Understanding Safety Regulations to Stay Ahead of Possible Impacts on Development of Additional GLP-1-Based Therapeutics

Time: 11:30 am
day: Conference Day Two


  • Reaffirming confidence in the safety of GLP-1 treatments to weigh up the possibility of further regulation on development of GLP-1 therapies
  • Considering the concerns of the European Medicine Agency (EMA) regarding the mental health side effects of GLP-1s to weigh up possible risks
  • Reflecting on how regulation could create new challenges in GLP-1 development and the impact this may have on commercial and clinical strategy, pricing, and reimbursement of GLP-1 therapies